Norio Ohmagari
Overview
Explore the profile of Norio Ohmagari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
593
Citations
11174
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ejima K, Ajelli M, Singh A, Chua H, Ponce L, Wang Y, et al.
Commun Med (Lond)
. 2025 Mar;
5(1):76.
PMID: 40082681
Background: In the absence of effective pharmaceutical interventions early in an infectious disease outbreak, non-pharmaceutical measures, especially isolating infected individuals, critically limit its impact. The ongoing COVID-19 pandemic has sparked...
2.
Saito S, Sakurai A, Matsumura Y, Uemura K, Hase R, Kato H, et al.
JAC Antimicrob Resist
. 2025 Mar;
7(2):dlaf027.
PMID: 40051884
Background And Objectives: Carbapenem-resistant Gram-negative bacilli (CRGNB), especially and , are critical pathogens associated with excess morbidity and mortality. To elucidate their molecular epidemiology and clinical outcomes in Japan, patients...
3.
Okumura N, Morino E, Nomoto H, Yanagi M, Takahashi K, Iwasaki H, et al.
Clin Infect Dis
. 2025 Feb;
PMID: 39982831
Background: This randomized controlled trial provided LC16m8 pre-exposure prophylaxis to high-risk individuals to assess its efficacy for mpox prevention, safety, and immunogenicity. Methods: This multicenter, randomized, open-label trial enrolled men...
4.
Furusawa Y, Kiso M, Uraki R, Sakai-Tagawa Y, Nagai H, Koga M, et al.
J Virol
. 2025 Feb;
:e0221724.
PMID: 39936915
Importance: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replicates efficiently at 37°C. However, the temperature of the human upper airway is 30°C-32°C. Therefore, the replicative ability of SARS-CoV-2 at low...
5.
6.
Uehara T, Yotsuyanagi H, Ohmagari N, Doi Y, Yamato M, Imamura T, et al.
Antiviral Res
. 2025 Feb;
236:106097.
PMID: 39892563
The impact of treatment-emergent amino acid substitutions (TEAASs) in severe acute respiratory syndome coronavirus 2 (SARS-CoV-2) 3C-like protease (3CL) on clinical and virologic outcomes was evaluated in patients with mild-to-moderate...
7.
Duration of infectious virus shedding of SARS-CoV-2 Omicron variant among immunocompromised patients
Kamegai K, Itoh N, Ishikane M, Iwamoto N, Asai Y, Akazawa-Kai N, et al.
J Infect Chemother
. 2025 Jan;
31(4):102631.
PMID: 39848541
Objective: The duration of viral shedding and criteria for de-isolation in the hospital among immunocompromised patients with coronavirus disease 2019 (COVID-19) remain unclear. This study aimed to evaluate viral shedding...
8.
Maruki T, Ishikane M, Kurokawa M, Kubo T, Miyazato Y, Ohmagari N
Jpn J Infect Dis
. 2025 Jan;
PMID: 39756960
Guidelines for sexually transmitted infections recommend oral metronidazole (MNZ) as the first-line treatment option for vaginal trichomoniasis; however, there have been cases of prolonged symptoms or recurrence after treatment. To...
9.
Jeong H, Park S, Chun J, Ohmagari N, Kim Y, Tsuzuki S
J Infect Public Health
. 2024 Dec;
18(2):102629.
PMID: 39733687
Background: The social contact data for Japan as of 2022 showed a substantially decreased number of contacts compared with before the COVID-19 pandemic. However, it is unclear whether social contact...
10.
Makram A, Elsheikh R, Makram O, Van N, Nam N, Quan N, et al.
BMC Med Res Methodol
. 2024 Dec;
24(1):300.
PMID: 39668366
No abstract available.